Targets › CYBB
3 programs from 2 companies in 5 trials: 5 Phase 1; Hematology, Infectious disease, Immunology; next expected readout Jul 2027.
Catalytic subunit of the phagocyte NADPH oxidase complex that mediates the transfer of electrons from cytosolic NADPH to O2 to produce the superoxide anion (O2(-)). In the activated complex, electrons are first transferred from NADPH to flavin adenine dinucleotide (FAD) and subsequently transferred via two heme molecules to molecular oxygen, producing superoxide through an outer-sphere reaction (Probable). (UniProt, P04839)
Open in Phaseline: the race on CYBB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | gp91 Grans mRNA-transfected granulocytes delivering functional gp91phox (NADPH oxidase component) | CYBB | Phase 1 | Chronic Granulomatous Disease | Jul 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Base-edited hematopoietic stem and progenitor cells (autologous) Base editing to repair CYBB gene mutation | CYBB | Phase 1 | CD40L-HyperIgM Syndrome; Chronic Granulomatous Disease (CGD) | Oct 2027 |
| Ensoma | EN-374 Gene therapy delivering functional CYBB gene to restore NADPH oxidase activity in neutroph | CYBB | Phase 1 | X-Linked Chronic Granulomatous Disease | Dec 2027 |
CD40L-HyperIgM Syndrome (2) Chronic Granulomatous Disease (1) Chronic Granulomatous Disease (CGD) (1) X-Linked Chronic Granulomatous Disease (1)
protein or peptide (1), mixed (1), other (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) Ensoma (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.